



**MDwise PDL Changes April 2009 DUR Board Presentation
For Hoosier Healthwise PDL**

Additions to PDL with NO Clinical Edits

None

Additions to PDL with Clinical Edits

Product	Rationale
RELENZA (Zanamivir) QLL	1 course of therapy / 6 months
BANZEL (Rufinamide) PA	Approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults.

Changes to or Additions of Clinical Edits

Product	Rationale
NA	

Remove from PDL

Product	Rationale
NA	